Diagnosis and treatment of CD20 negative B cell lymphomas

CD20 negative B cell non-Hodgkin lymphoma (NHL) is rare and accounts for approximately 1-2% of B cell lymphomas. CD20- negative NHL is frequently associated with extranodal involvement, atypical morphology, aggressive clinical behaviour, resistance to standard chemotherapy and poor prognosis. The mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Katchi, Tasleem, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297138/
https://www.ncbi.nlm.nih.gov/pubmed/28191314
http://dx.doi.org/10.1186/s40364-017-0088-5
_version_ 1782505684825276416
author Katchi, Tasleem
Liu, Delong
author_facet Katchi, Tasleem
Liu, Delong
author_sort Katchi, Tasleem
collection PubMed
description CD20 negative B cell non-Hodgkin lymphoma (NHL) is rare and accounts for approximately 1-2% of B cell lymphomas. CD20- negative NHL is frequently associated with extranodal involvement, atypical morphology, aggressive clinical behaviour, resistance to standard chemotherapy and poor prognosis. The most common types of these include plasmablastic lymphoma, primary effusion lymphoma, large B-cell lymphoma arising from HHV8-associated multicentric Castleman’s disease, and ALK+ large B cell lymphoma. This review provides an overview of the diagnostic and treatment modalities for CD20 negative B cell NHL.
format Online
Article
Text
id pubmed-5297138
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52971382017-02-10 Diagnosis and treatment of CD20 negative B cell lymphomas Katchi, Tasleem Liu, Delong Biomark Res Review CD20 negative B cell non-Hodgkin lymphoma (NHL) is rare and accounts for approximately 1-2% of B cell lymphomas. CD20- negative NHL is frequently associated with extranodal involvement, atypical morphology, aggressive clinical behaviour, resistance to standard chemotherapy and poor prognosis. The most common types of these include plasmablastic lymphoma, primary effusion lymphoma, large B-cell lymphoma arising from HHV8-associated multicentric Castleman’s disease, and ALK+ large B cell lymphoma. This review provides an overview of the diagnostic and treatment modalities for CD20 negative B cell NHL. BioMed Central 2017-02-07 /pmc/articles/PMC5297138/ /pubmed/28191314 http://dx.doi.org/10.1186/s40364-017-0088-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Katchi, Tasleem
Liu, Delong
Diagnosis and treatment of CD20 negative B cell lymphomas
title Diagnosis and treatment of CD20 negative B cell lymphomas
title_full Diagnosis and treatment of CD20 negative B cell lymphomas
title_fullStr Diagnosis and treatment of CD20 negative B cell lymphomas
title_full_unstemmed Diagnosis and treatment of CD20 negative B cell lymphomas
title_short Diagnosis and treatment of CD20 negative B cell lymphomas
title_sort diagnosis and treatment of cd20 negative b cell lymphomas
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297138/
https://www.ncbi.nlm.nih.gov/pubmed/28191314
http://dx.doi.org/10.1186/s40364-017-0088-5
work_keys_str_mv AT katchitasleem diagnosisandtreatmentofcd20negativebcelllymphomas
AT liudelong diagnosisandtreatmentofcd20negativebcelllymphomas

Ejemplares similares